WallStSmart

JIADE LIMITED Common stock (JDZG)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 907% more annual revenue ($258.90M vs $25.70M). ZEPP leads profitability with a -15.5% profit margin vs -41.2%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

JDZG

Hold

39

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 8.0
Piotroski: 3/9Altman Z: 4.79

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JDZG.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JDZG4 strengths · Avg: 9.8/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
66.2%10/10

Revenue surging 66.2% year-over-year

Altman Z-ScoreHealth
4.7910/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

JDZG4 concerns · Avg: 2.5/10
Market CapQuality
$5.26M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-11.0%2/10

ROE of -11.0% — below average capital efficiency

EPS GrowthGrowth
-91.4%2/10

Earnings declined 91.4%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : JDZG

The strongest argument for JDZG centers on Price/Book, Revenue Growth, Altman Z-Score. Revenue growth of 66.2% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : JDZG

The primary concerns for JDZG are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

JDZG is growing revenue faster at 66.2% — sustainability is the question.

Monitor INFORMATION TECHNOLOGY SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 39/100) and 43.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

JIADE LIMITED Common stock

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · China

JIADE LIMITED (Ticker: JDZG) is an innovative enterprise at the intersection of technology and e-commerce, dedicated to transforming consumer experiences through cutting-edge solutions. With a strong emphasis on sustainable growth, the company actively invests in research and development to stay ahead of emerging market trends. JIADE's strategic partnerships and commitment to a customer-centric model enhance its competitive positioning, making it a compelling opportunity for institutional investors focused on long-term value creation and growth potential.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?